Approval by the FDA of Flexion Therapeutics Inc.'s Zilretta whetted the appetite for more non-opioid drugs, the lack of which has left officials at pain-focused Centrexion Therapeutics Inc. "awestruck," Chief Medical Officer Randall Stevens told BioWorld.